Iams Wealth Management LLC Purchases New Stake in Bristol Myers Squibb Company $BMY

Iams Wealth Management LLC purchased a new position in Bristol Myers Squibb Company (NYSE:BMY) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 24,964 shares of the biopharmaceutical company’s stock, valued at approximately $1,558,000.

A number of other large investors have also bought and sold shares of the stock. Davis Asset Management L.P. purchased a new stake in shares of Bristol Myers Squibb during the second quarter valued at approximately $27,000. Bayban bought a new position in shares of Bristol Myers Squibb in the fourth quarter worth approximately $31,000. Addison Advisors LLC bought a new position in shares of Bristol Myers Squibb in the second quarter worth approximately $32,000. Groupe la Francaise increased its stake in shares of Bristol Myers Squibb by 562.9% in the second quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 501 shares during the period. Finally, Arlington Trust Co LLC purchased a new position in shares of Bristol Myers Squibb in the second quarter worth $35,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Pipeline progress supports the investment case. Bristol Myers reported positive Phase 3 results for RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors and ZENBEXUS (iberdomide) in relapsed or refractory multiple myeloma. The data increase confidence that newer therapies can help offset future pressure on established products. How Mixed Admilparant Results and Strong Oncology Data Will Impact Bristol Myers Squibb Investors
• Positive Sentiment: Admilparant remains commercially viable, according to UBS. Although the pulmonary-fibrosis drug produced mixed Phase 3 results, the lower dose met the primary endpoint, and UBS said the LPA1 antagonist still has a path forward. That assessment limits the downside from the trial news and preserves a potential new growth opportunity. Bristol-Myers Squibb’s Pulmonary Fibrosis Treatment Still Viable Despite Recent Mixed Phase 3 Results, UBS Says
• Positive Sentiment: Some analyst support remains constructive. Truist maintained its Buy rating on BMY, helping reinforce the view that the valuation and pipeline offer upside despite ongoing execution risks. Truist Financial Sticks to Its Buy Rating for Bristol-Myers Squibb

Insiders Place Their Bets

In related news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the sale, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.05% of the stock is currently owned by company insiders.

Bristol Myers Squibb Trading Up 2.1%

NYSE BMY opened at $60.51 on Friday. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.64. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The stock has a 50 day simple moving average of $63.65 and a two-hundred day simple moving average of $60.30. The stock has a market cap of $123.60 billion, a P/E ratio of 13.33, a price-to-earnings-growth ratio of 0.30 and a beta of 0.19.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. The firm had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. During the same period last year, the company earned $1.46 EPS. The business’s quarterly revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, analysts forecast that Bristol Myers Squibb Company will post 6.65 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be paid a $0.63 dividend. The ex-dividend date of this dividend is Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.51%.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Truist Financial reiterated a “buy” rating and set a $70.00 price target (up from $65.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. TD Cowen assumed coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “buy” rating on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Daiwa Securities Group boosted their price objective on shares of Bristol Myers Squibb from $53.00 to $66.00 and gave the company a “neutral” rating in a research report on Tuesday, August 4th. Finally, Raymond James Financial initiated coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a “strong-buy” rating for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Bristol Myers Squibb has an average rating of “Hold” and a consensus price target of $64.88.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.